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Protein transduction domains (PTDs) are peptides that afford the internalization of cargo macromolecules (including plasmid DNA, proteins,
liposomes, and nanoparticles). In the case of polycationic peptides, the efficiency of PTDs to promote cellular uptake is directly related to their
molecular mass or their polyvalent presentation. Similarly, the efficiency of routing to the nucleus increases with the number of nuclear
localization signals (NLS) associated with a cargo. The quantitative enhancement, however, depends on the identity of the PTD sequence as well
as the targeted cell type. Thus the choice and multivalent presentation of PTD and NLS sequences are important criteria guiding the design of
macromolecules intended for specific intracellular localization. This review outlines synthetic and recombinant strategies whereby PTDs and
signal sequences can be assembled into multivalent peptide dendrimers and promote the uptake and routing of their cargoes. In particular, the
tetramerization domain of the tumour suppressor p53 (p53tet) is emerging as a useful scaffold to present multiple routing and targeting moieties.
Short cationic peptides fused to the 31-residue long p53tet sequence resulted in tetramers displaying a significant enhancement (up to 1000 fold) in
terms of their ability to be imported into cells and delivered to the cell nucleus in relation to their monomeric analogues. The design of future
polycationic peptide dendrimers as effective delivering vehicles will need to incorporate selective cell targeting functions and provide solutions to
the issue of endosomal entrapment.
© 2005 Elsevier B.V. All rights reserved.1. The concept of multivalency and its applications
Multivalency (or polyvalency) refers to the presence of mul-
tiple copies of a functional element within a single molecule. In
terms of receptor–ligand interactions, a multivalent ligand may
interact with a multivalent receptor or a cluster of monovalent
receptors [1]. Multivalent interactions are commonly observed
in biological systems; examples include viral and bacterial ad-
hesion to host cell surfaces, host cell–cell interactions, and
many aspects of the humoral immune response. A major advan-
tage conferred by multivalent interactions is the often dramatic
enhancement in avidity of a polyvalent ligand for its receptor
over the affinity of a monovalent counterpart [2,3]. More spe-Abbreviations: Antp Drosophila, antennapedia homeodomain; NLS, nucle-
ar localization sequence; Np, nucleoplasmin; p53mono, monomeric form of
human p53 tetramerization domain (residues 325–355) harbouring a L334P
mutation; p53tet, human p53 tetramerization domain (residues 325–355); PTD,
protein transduction domain; scFv, single-chain antibody; Tat, HIV-1 transacti-
vator of transcription
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doi:10.1016/j.bbamem.2005.11.016cifically, the display of several spacially proximal ligands within
a molecular scaffold results in a greatly increased local concen-
tration of recognition elements near a targeted receptor, a phe-
nomenon known as the chelate effect [1,4,5].
One of the earliest examples of multivalent interactions is
the oligomerization or duplication of a protein ligand such as an
Ig domain (exemplified by the structure of IgG and IgM) or a
lectin-binding motif (such as the binding subunits of cholera
toxin and Shiga toxin) [6]. This concept has recently been
exploited for the design of single-chain antibodies (scFv) oli-
gomers. Specifically, scFv's are genetically engineered anti-
body fragments built by linking the VH and VL chains of a
known antibody through a flexible linker to produce a single
polypeptide chain mimic of the original Fab domain [7]. Be-
cause of their small size (∼27 kDa) and the practical fact that
they are amenable to expression as recombinant proteins,
scFv's have become popular reagents for antibody-based ther-
apies [8]. However, their reduced mass and monovalency also
shorten their in vivo half-lives due to rapid renal clearance. By
fusing an oligomerization motif to the scFv domain, non-cova-
lent dimer (diabodies), trimers (triabodies) and tetramers
Fig. 1. The importance of cationic peptide mass and PTD-to-cargo ratio in
enhancing the cellular uptake of macromolecules. (A) Linear relationship link-
ing an increase in molecular mass of poly-L-lysine (○), poly-D-lysine (▵) and
poly-L-ornithine (□) conjugated to radiolabelled human serum albumin to the
enhancement in cellular uptake of the resulting complex relative to radiolabelled
albumin alone (adapted from [20]). (B) Tat peptides were attached to the surface
of radiolabelled superparamagnetic iron oxide nanoparticles at various ratios
and its uptake expressed relative to the nanoparticle with the lowest Tat peptide/
nanoparticle ratio (redrawn from [29]).
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increases in both in vivo half-lives, tumour uptake and resi-
dence time in tumours [9–13]. The use of oligomerization
domains to create multivalent scFv's is essentially reminiscent
of the multivalent architecture of IgG and IgM molecules.
Polyvalent scFv's represent but one example of a more
general phenomenon in which the multivalent display of a
targeting function on a macromolecule can lead to a quantita-
tive increase in localization of such constructs to cells. A
number of publications have described the relationship between
valency and avidity, mostly as it pertains to the design of
synthetic multivalent ligands for use as inhibitors and activators
[1,3,14]. Protein transduction domains (PTDs) and in particular
polycationic peptides have also been used to shuttle macromo-
lecules such as DNA, proteins and other cargoes across cellular
membranes. This review will highlight the importance of
valency effects in designing effective PTD-containing macro-
molecules and its impact in terms of cellular import with a
focus on polycationic cell-penetrating peptides. Examples of
covalent and non-covalent strategies for displaying multiple
copies of PTD peptides onto macromolecules will be discussed
in the context of enhancing the uptake of such conjugates by
cells. In this regard, short self-assembling peptides derived
from known oligomerization domains of proteins are emerging
as excellent scaffolds for generating defined protein-like con-
structs displaying multiple PTD domains. More precisely, we
report our recent progress in using the human p53 tetrameriza-
tion domain, in promoting the cellular uptake and nuclear
routing of cationic peptides.
1.1. A role for multivalency in transduction and transfection
mediated by polycationic PTDs
Polycationic peptide sequences such as polylysine, polyar-
ginine and polyornithine are known for their cell penetrating
properties [15–17]. From a historical perspective, Ryser had
demonstrated in 1965 that homopolymers of cationic amino
acids were able to facilitate the import of albumin into adherent
cell monolayers as well as cell suspensions [18,19]. More
importantly, the level of albumin import correlated directly
with the molecular size of the polycations (Fig. 1A) [20]. The
correlation further suggested that a minimal peptide mass of
500 to 900 Da, corresponding to 4 to 8 amino acids in length,
was necessary to effect albumin import [20]. This projection
was subsequently proven with the discovery that short arginine-
and lysine-rich peptides derived from the HIV-1 transactivator
of transcription domain (Tat peptide), the third helix of the
Drosophila Antennapedia homeodomain (Antp peptide), and
herpesvirus VP22 could facilitate protein transduction, DNA
transfection and the shuttling of other macromolecular cargoes
into eukaryotic cells in the context of in vitro and in vivo
experiments [21–23]. Although these peptides are at the low
end of peptide masses proposed by Ryser to cause cellular
uptake [18,20], they are surprisingly efficient at importing a
wide range of cargoes into cells. Multivalency may provide the
rationale for the observed effectiveness of PTD peptides. A role
for multivalency in enhancing the internalization property ofshort cationic peptides was first demonstrated by Gariépy and
coworkers who showed that the assembly of pentalysine
sequences into a multivalent scaffold can mimic the enhance-
ment of cellular uptake observed by Ryser for much longer
cationic peptide polymers [24–28]. More recently, the level
of conjugation of HIV-1 Tat peptides to superparamagnetic
nanoparticles was shown to influence their cellular uptake by
mouse lymphocytes (Fig. 1B) [29]. Specifically, the coupling
of up to 15 Tat peptides linked per nanoparticle generated a
100-fold increase in relative uptake. Both Fig. 1A and B
indicate, in two distinct experiments, that a threshold value
must be reached before the level of cellular uptake becomes
linearly related to the mass of a polycationic peptide or to the
PTD-to-cargo ratio. The biphasic nature of the curve in Fig.
1B suggests that one mechanism of cellular uptake becomes
dominant when a threshold of PTD-to-particle (valency num-
ber) is reached.
1.2. Oligomerization of a cargo results in a multivalent display
of PTDs
An analysis of the published literature to date on the use of
short cationic PTD peptides provides many examples linking
Table 1
A representative list of multivalent PTD-based systems in the literature
Oligomerization
state
Cargoes PTDs References
Dimer β-galactosidase Tat [30–32]
Superoxide dismutase Tat [33,34]
Oligolysine (9) [35]
Caspase-3 Tat [36]
Thymidine kinase Tat [37]
HSV-1 VP22 [38,39]
Tetramer Ovalbumin Tat [40–42]
p53 HSV-1 VP22 [22]
Oligoarginine (11) [43,44]
Avidin/Streptavidin Tat [45]
Antp [46,47]
Catalase Tat [48,49]
Beta-glucuronidase Tat [50]
Hexamer Glutamate
dehydrogenase
Tat [51]
Octamer Rhodamine Loligomers [52]
CTL antigen Loligomers [26]
Oligomer p16(INK4a) Tat [53,54]
multivalent Antp [55]
complex Human Serum
Albumin
poly-L-lysine [18,20]
Liposome/lipid
envelope
Tat [56,57]
Antp [58,59]
Oligoarginine (8) [60]
Nanoparticles Tat [61–63]
DNA/plasmids Tat [64–66]
Antp [67]
Poly-L-lysine [68–70]
Oligolysines [71]
Loligomers [27]
Heparan Sulfate Tat [72]
Aggregated
Complex ⁎
Grb10 SH2 domain Antp [73]
BH4 domain of
Bcl-XL
Tat [74]
FNK, a Bcl-XL
derivative
Tat [75]
CRAC domain of
benzodiazepine
receptor
Tat [76]
Influenza matrix
protein epitope
Tat [77]
⁎ Peptide sequences evaluated using TANGO algorithm [78,79] to determine
the likelihood of α-helix and β-sheet driven aggregation.
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peptides (Table 1). In many instances, it is the cargo itself that
affords the multivalent assembly of PTDs, when the cargo
naturally exists in an oligomeric state. For example, several
types of PTD sequences (Antp, VP22 and oligoarginine) have
been fused to human p53, a tumour suppressor containing a
tetramerization domain (Table 1). Proteases such as Cu,Zn-
superoxide dismutase, which form a highly stable dimer [80–
82], and β-galactosidase, a highly thermostable dimer at alka-
line pH [83–85], retain their quaternary structure even when
fused as cargoes to PTDs [83,84,86,87]. Avidin and streptavi-
din can present either four copies of PTDs when both entities
are engineered as fusion proteins [88,89] or up to four copies ofPTDs per avidin/streptavidin when these proteins are mixed
with biotinylated PTD peptides [90].
1.3. Self-aggregation, complexation and covalent attachment
lead to the macromolecular display of multiple PTD peptides
Aggregation, complexation, and coupling mechanisms have
either been observed or exploited to pair multiple PTD peptides
with a cargo such as plasmid DNA, liposomes or nanoparticles
[57,59,62,66]. Torchilin and Levchenko's groups have reported
the preparation of liposomes incorporating the PEGylated lipid
p-nitrophenylcarbonyl-PEG-phosphatidylethanolamine (pNP-
PEG-PE) as a strategy to attach Tat peptides through the p-
nitrophenylcarbonyl moieties on the liposome surface [57]. On
average, over 100 Tat peptides were presented on the surface of
each liposome [57]. In addition, these authors reported the
transfection of mouse fibroblasts as well as Lewis lung carci-
noma tumour cells in the mouse using Tat peptide-attached
liposome preparations containing only a small quantity (≤10
mol%) of cationic lipids (to further promote DNA condensa-
tion) [91,92]. In their study, Tseng et al. demonstrated that both
Tat and Antp peptides can enhance the efficiency of transloca-
tion of liposomes in proportion to the number of peptides
attached to the liposomal surface [59]. Their work also showed
that the observed enhancement in cellular uptake was depen-
dant on the PTD peptide used and the cell line being trans-
fected. Specifically, the addition of five Tat peptides/liposome
produced almost a 100-fold increase in liposome translocation,
while 50 Antp peptides/liposome were necessary to observe a
significant translocation enhancement in comparison to non-
conjugated liposomes. The dextran coat covering magnetic
nanoparticles has also be modified with Tat peptides to achieve
a high valency of approximately 20 peptides per nanoparticle
[29,93]. Such particles have been used to track hematopoietic
stem cells and antigen-specific T lymphocytes [62,94]. As in
the case of liposomes, the internalization efficiency of such
particles was proportional to the number of PTD peptides
conjugated to their surface [29].
Branched peptides containing eight PTD peptides have also
been useful in condensing DNA for cell transduction purposes
[27]. Specifically, plasmid DNA needed to be condensed and its
negative charges neutralized with cationic peptide dendrimers
in order to create DNA–peptide complexes capable of being
internalized by cells. For instance, Singh et al. showed that a
minimal weight ratio of 0.5 of a nucleus-directed polycationic
peptide dendrimer termed loligomer 4 was needed to abolish
the electrophoretic mobility of a condensed peptide/plasmid
complex [27]. For optimal transfection efficiency, the loligomer
4:plasmid ratio needed to be even higher (about 3) [27].
Finally, the multivalent presentation of PTD peptides may
also occur as a result of an aggregation event with their cargo
molecules. For instance, fusion constructs of Antp and Tat
PTDs with peptide/protein cargoes such as the Grb10 SH2
domain or the BH4 domain of Bcl-XL are predicted to form
molecular aggregates in solution by virtue of a stretch of 5 or
more amino acids in the cargo peptide sequences which dis-
plays a greater than 50% probability of undergoing β-strand
358 M. Sung et al. / Biochimica et Biophysica Acta 1758 (2006) 355–363driven aggregation, as predicted using the algorithm TANGO.
This algorithm calculates the propensity of peptide sequence
in forming secondary structure-based aggregates [78,79]
(Table 1).
In summary, the physical features of a cargo as well as the
methods of introducing PTD peptides onto a cargo can readily
lead to the assembly of conjugates or complexes presenting
multiple copies of a PTD peptide.
1.4. The rate of nuclear import is also dependent on the
number of nuclear localization sequences associated with a
cargo
Intracellular routing signals, in particular the SV40 large T-
antigen nuclear localization sequence (NLS), have been exten-
sively used to further relocate a fraction of imported molecules
to the nucleus of targeted cells in an effort to deliver agents
such as photosensitizers near nucleic acids [95].
Laskey and coworkers were the first investigators to dem-
onstrate the existence of a nuclear localization domain while
studying the protein nucleoplasmin (Np), an acidic protein
abundantly expressed in the Xenopus oocyte nucleus. Np is a
pentamer in which a bipartite NLS is incorporated in the C-
terminal tail domain of each Np monomer. Laskey's group
showed that microinjecting Np pentamers containing a single
NLS tail (instead of five) per unit into the cytoplasm of oocytes
was sufficient for transport of the protein into the oocyte nu-
cleus [96]. More importantly, the rate of accumulation of Np in
the cell nucleus depended on the number of NLS present per
pentamer [96]. Dworetzky et al. subsequently showed that the
relative nuclear uptake of gold nanoparticles coated with Np or
BSA conjugated with the SV40 large T-antigen NLS increases
with the number of NLS associated with such particles [97]. In
summary, the import and the routing of macromolecules to the
cell nucleus are events that can be enhanced through valency
effects. Incidentally, since NLS sequences are by their very
nature arginine- and lysine-rich peptides, they may also by
themselves serve as PTD domains.
1.5. Incorporating multivalency into the design of PTD-
containing vehicles
Both covalent and non-covalent approaches can be used to
design constructs or cargoes harbouring multiple copies of cell-
penetrating and intracellular routing peptides. The simplest but
least controlled approach is the covalent integration of PTD and
NLS sequences into protein or macromolecular scaffolds using
chemical crosslinkers to produce complexes with high peptide-
to-cargo ratios (high valency). Polylysine has been randomly
coupled to larger macromolecules (serum albumin) to create
macroscopic drug carriers [98].
Alternatively, polylysine chains have been assembled in a
systematic way onto branched lysine core peptides called loli-
gomers [26,27]. The term loligomer is derived from the Latin
root loligo referring to members of the squid family, thereby
emphasizing the branched or “squid-like” nature of these pep-
tides. Loligomers have been designed to contain eight SV40large T-antigen NLS sequences as well as eight pentalysine
stretches acting as PTD sequences which allow such peptide
dendrimers to penetrate cells and relocate to their nucleus [52].
Loligomers also include a C-terminal arm to introduce reporter
groups into their structures [28]. These peptide dendrimers
typically outperform their linear, monomeric homologues (one
arm of the dendrimer incorporating the PTD and NLS
sequences) in terms of cellular uptake and nuclear localization
into CHO cells [52]. Loligomers harbouring antigenic epitopes
have also been shown to generate cytotoxic T-cell responses
[26]. Although the loligomer design is a significant improve-
ment from the linear presentation of cationic PTD sequences,
their assembly by solid-phase peptide synthesis places limits on
the size and homogeneity of the final constructs.
Recombinant approaches offer a defined, systematic ap-
proach to incorporate PTD and NLS peptides into fusion con-
structs. For example, protein constructs can be engineered to
integrate a linear series of routing peptides. As the size of such
peptides increases, the resulting constructs are expected to adopt
a tertiary structure (tertiary fold) that may interfere with the
presentation of individual domains. By introducing an oligomer-
ization domain within linear peptide constructs, peptide dendri-
mers can instead be created. This display strategy would guide
the folding on such peptides into known quaternary structures
(as dictated by the oligomerization domain) and permit the
equivalent exposure of multiple routing domains via several N-
and C-termini. As a prerequisite, these self-assembling domains
must be encoded by relatively short peptide sequences and must
create stable quaternary structures. Coil-coiled sequences (leu-
cine zipper; multiple of heptad sequences of 28 to 35 amino
acids in length) [99] and the p53 tetramerization domain (p53tet;
31 amino acids) represent established examples of oligomeriz-
ing sequences. The p53tet domain offers the advantage of form-
ing tetrameric peptide dendrimers that approximate the 8-branch
scaffold of loligomers (tetramers with 4 N- and 4 C-terminal
sites for introducing functional domains). In summary, the in-
corporation of a self-assembling domain into a linear peptide
sequence permits the use of standard recombinant approaches to
string together routing and functional domains in a modular
fashion. This modular approach to designing peptide dendrimers
as delivery vehicles represents a powerful approach for exploit-
ing the concept of valency in enhancing the delivery of cargoes
into cells and tissues.
1.6. Peptide dendrimers based on the non-covalent assembly of
peptides incorporating the p53 tetramerization domain
Peptide-based delivery vehicles can be assembled into den-
drimers by inserting the minimal tetramerization domain of
human tumour suppressor p53 within their sequence. This
tetramerization domain is a 31-amino acid long peptide repre-
senting residues 325 to 355 of human p53. It self-assembles
into a stable tetramer with a melting temperature near 80 °C
under physiological conditions [100]. The crystal and NMR
structures of p53tet indicate that residues 325–255 forms a
“dimer of dimers” in which each monomer adopts a β strand-
turn-α helix fold conformation [101] (Fig. 2A). In order to
Fig. 2. Ribbon representations of (A) the minimal p53 tetramerization domain (325–355) from coordinates derived by NMR spectroscopy (Protein Data Bank code:
1PES [101]) and (B) a deca-arginyl-p53tet fusion construct (10R-p53tet) where a sequence of 10 arginine residues was fused to the N-terminus of the minimal p53
tetramerization domain. This model was constructed from the Swiss PDB Viewer Molecule Builder and Energy Minimization functions.
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effects previously observed for loligomers, we have recently
constructed peptides (by synthetic or recombinant approaches)
in which PTDs as well as other functional motifs were directly
fused to either the C- or N-terminus of the p53 tetramerizationFig. 3. Specific retention of fluorescein-labelled 10R-p53tet peptides localized to
the nucleus of CHO cells following the removal of peptides from the cell
medium. (A) Retention of either tetrameric (10R-p53tet, ▪) or monomeric
forms (10R-p53mono; L334P mutation [102], •) of fluorescein-labelled con-
structs peptides in CHO cells as measured by flow cytometry following the
removal of the peptides from the medium 6 h post incubation. Cells were
originally exposed to a 0.5-μM solution of one of the peptides in medium for
6 h and were subsequently incubated in peptide-free medium for an additional
18 h. (B and C) Superimposed phase-contrast and confocal images of viable
CHO cells taken 18 h post incubation (12 h after the removal of peptides from
the medium) suggest that most of the remaining fluorescein-labelled peptides
(green colour) have localized to the cell nucleus. 10R-p53tet and 10R-p53mono
peptides were not toxic to CHO cells even at doses up to 25 μM.sequence. The resulting constructs were shown to self-assemble
into peptide dendrimers (tetramers). More specifically, we
have fused a deca-arginyl (10R), deca-lysyl (10K) or the
HIV-1 Tat sequence (GRKKRRQRRRAP; residues 48–60)
to the N-terminus of the p53tet domain. A ribbon model of
the structure of the deca-arginyl p53tet peptide is shown in
Fig. 2B. Peptides containing both the PTD sequences as well
as the NLS from the SV40 large T-antigen were also con-
structed. Monomeric versions (p53mono) of these tetrameric
peptide vehicles were generated by inserting a L334P muta-
tion within the p53 tetrameric domain [102]. Routing func-
tions such as the cellular uptake and nuclear localization of
the tetrameric constructs were shown to be dramatically en-
hanced with the resulting tetravalent peptides typically dis-
playing between 10- and 100-fold enhancement in cellular
import and intracellular routing properties in relation to their
monomeric analogues (Fig. 3A, first 6 h) [103]. These con-
structs were not toxic to cells. Flow cytometry results and
transfection assays indicated that tetravalent deca-arginyl pep-
tides (10R-p53tet and NLS-10R-p53tet) were the most effi-
ciently routed constructs into cells.
1.7. p53tet-based peptide dendrimers containing cationic PTDs
enter cells in a manner similar to PTDs linked to other cargoes
Mechanistic studies confirmed that deca-arginyl molecules
fused to a p53tet domain (10R-p53tet peptides) initially bind to
heparan sulfate carbohydrates on the cell surface and are inter-
nalized into eukaryotic cells via a clathrin-coated pit mediated
process [103]. Most of the imported peptides accumulate into
endosome-like vesicles. As shown in Fig. 3, when such peptides
were removed from the cell medium, most of the fluorescein-
labelled 10R-p53tet peptides eventually disappeared from the
cytosol with the exception of a significant fraction that had
relocated to the cell nucleus (Fig. 3B and C). Flow cytometry
data (Fig. 3A), however, indicate that the majority of the 10R-
p53tet peptides imported into cells were either degraded or
routed back to the extracellular space (exocytosis) without ever
reaching the cytosol. There is thus a need to develop strategies to
facilitate peptide escape from such vesicular compartments. pH
responsive peptides such as GALA have been shown to display
endosomolytic properties in vitro [104]. Polyhistidine
sequences, in view of their imidazole groups (pKa ∼6), may in
theory buffer the endosomal microenvironment in which the pH
360 M. Sung et al. / Biochimica et Biophysica Acta 1758 (2006) 355–363drops to 5. This buffering capacity would act as a “proton
sponge” that eventually may rupture the endosomal membrane
and allow peptide escape [105–108].
Other targeting functions must also be embedded into these
peptide dendrimers to increase their therapeutic potential. As an
example, delivery vehicles are needed to selectively target
cancer cells. Receptors for short peptide hormones such as
LHRH and somatostatin (octreotide) analogues are overex-
pressed on certain cancer cells [109–111] and as such, these
peptides could be fused to p53tet containing peptides. It is,
however, hoped that short peptides or small protein domains
derived from combinatorial peptide or protein library searches
may provide ligands with more selectivity for cancer cells
[112–114].
2. Summary
The multivalent presentation of PTDs and other routing
signals represents a powerful method for enhancing the cellular
uptake and nuclear localization of many cargo macromole-
cules. Multivalency can be achieved using the oligomeric
potential of the cargo macromolecule or by designing highly
functionalized peptide dendrimers using synthetic or recombi-
nant methods. The tetramerization domain of human p53 is a
useful scaffold that is amenable to recombinant manipulation
to present multiple equivalents of routing and targeting moi-
eties. p53tet-based constructs harbouring tetravalent oligoca-
tionic signals have been shown to efficiently enter cells and
localize to their nucleus relative to their monomeric homo-
logues. Future development of these delivery vehicles will
involve incorporating other functional moieties that limit
endosomal trapping and afford selectivity for molecular tar-
gets on cancer cells.
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